Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.

Pincus SH, Song K, Maresh GA, Frank A, Worthylake D, Chung HK, Polacino P, Hamer DH, Coyne CP, Rosenblum MG, Marks JW, Chen G, Weiss D, Ghetie V, Vitetta ES, Robinson JE, Hu SL.

J Virol. 2017 Jan 18;91(3). pii: e01360-16. doi: 10.1128/JVI.01360-16. Print 2017 Feb 1.

2.

Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.

Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG.

Mol Cancer Ther. 2013 Jun;12(6):979-91. doi: 10.1158/1535-7163.MCT-13-0002. Epub 2013 Mar 14.

3.

Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.

Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG.

Oncogene. 2014 Jan 23;33(4):429-39. doi: 10.1038/onc.2012.612. Epub 2013 Feb 4.

4.

The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.

Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG.

J Invest Dermatol. 2013 Apr;133(4):1052-62. doi: 10.1038/jid.2012.402. Epub 2012 Nov 29.

5.

The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.

Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG.

Biochem Pharmacol. 2012 Aug 15;84(4):451-8. doi: 10.1016/j.bcp.2012.05.019. Epub 2012 Jun 9.

PMID:
22687624
6.

Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin.

Lyu MA, Cheung LH, Hittelman WN, Liu Y, Marks JW, Cho MJ, Rosenblum MG.

Cancer Lett. 2012 Sep 28;322(2):159-68. doi: 10.1016/j.canlet.2012.02.029. Epub 2012 Mar 1.

PMID:
22388102
7.

Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells.

Berger CS, Marks JW, Bolskar RD, Rosenblum MG, Wilson LJ.

Transl Oncol. 2011 Dec;4(6):350-4. Epub 2011 Dec 1.

8.

Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG.

Mol Cancer Ther. 2012 Jan;11(1):143-53. doi: 10.1158/1535-7163.MCT-11-0519. Epub 2011 Nov 16.

9.

Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.

Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, Winkles JA.

Mol Cancer Ther. 2011 Jul;10(7):1276-88. doi: 10.1158/1535-7163.MCT-11-0161. Epub 2011 May 17.

10.

The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.

Lyu MA, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Rosenblum MG.

Biochem Pharmacol. 2010 Nov 1;80(9):1335-42. doi: 10.1016/j.bcp.2010.07.017. Epub 2010 Jul 21.

PMID:
20654581
11.

The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.

Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG.

Neoplasia. 2010 May;12(5):366-75.

12.

Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.

Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG.

Cancer Res. 2009 Dec 1;69(23):8987-95. doi: 10.1158/0008-5472.CAN-09-2693. Epub 2009 Nov 24.

13.

The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.

Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG.

Mol Cancer Ther. 2007 Feb;6(2):460-70. Epub 2007 Jan 31.

14.

Stable containment of radionuclides on the nanoscale by cut single-wall carbon nanotubes.

Mackeyev YA, Marks JW, Rosenblum MG, Wilson LJ.

J Phys Chem B. 2005 Mar 31;109(12):5482-4.

PMID:
16851586
15.

Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody.

Ashcroft JM, Tsyboulski DA, Hartman KB, Zakharian TY, Marks JW, Weisman RB, Rosenblum MG, Wilson LJ.

Chem Commun (Camb). 2006 Jul 28;(28):3004-6. Epub 2006 Jun 9.

PMID:
16832518
16.

Aptamer:toxin conjugates that specifically target prostate tumor cells.

Chu TC, Marks JW 3rd, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, Levy M.

Cancer Res. 2006 Jun 15;66(12):5989-92.

17.

Silent PPOs: the stealth discounting of provider reimbursement.

Marks JW.

J Med Pract Manage. 2005 Sep-Oct;21(2):85-8.

PMID:
16302436
18.

Maximizing reimbursement by appealing claim denials.

Marks JW.

J Med Pract Manage. 2005 Jan-Feb;20(4):177-9.

PMID:
15779512
19.
20.

Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells.

Mehta K, Ocanas L, Malavasi F, Marks JW, Rosenblum MG.

Mol Cancer Ther. 2004 Mar;3(3):345-52.

21.
22.
23.

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.

Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG.

Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7866-71. Erratum in: Proc Natl Acad Sci U S A 2002 Aug 6;99(16):10941.

24.

Estrogen replacement therapy and gallbladder disease in postmenopausal women.

Uhler ML, Marks JW, Judd HL.

Menopause. 2000 May-Jun;7(3):162-7. Review.

PMID:
10810961
25.

Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.

Rosenblum MG, Marks JW, Cheung LH.

Cancer Chemother Pharmacol. 1999;44(4):343-8.

PMID:
10447583
26.
27.

High-dose preoperative radiation and the challenge of sphincter-preservation surgery for cancer of the distal 2 cm of the rectum.

Mohiuddin M, Regine WF, Marks GJ, Marks JW.

Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):569-74.

PMID:
9486606
28.

Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women.

Uhler ML, Marks JW, Voigt BJ, Judd HL.

J Clin Endocrinol Metab. 1998 Feb;83(2):410-4.

PMID:
9467549
29.

Nucleation of biliary cholesterol, arachidonate, prostaglandin E2, and glycoproteins in postmenopausal women.

Marks JW, Uhler ML, Bonorris GG, Judd HL.

Gastroenterology. 1997 Apr;112(4):1271-6.

PMID:
9098012
30.

Effects of ursodiol or ibuprofen on contraction of gallbladder and bile among obese patients during weight loss.

Marks JW, Bonorris GG, Schoenfield LJ.

Dig Dis Sci. 1996 Feb;41(2):242-9.

PMID:
8601365
31.

Natural history and treatment with ursodiol of gallstones formed during rapid loss of weight in man.

Marks JW, Stein T, Schoenfield LJ.

Dig Dis Sci. 1994 Sep;39(9):1981-4.

PMID:
8082507
32.

Recurrence of gallstones following nonsurgical therapy with extracorporeal shock-wave lithotripsy.

Marks JW.

Gastroenterology. 1994 Jan;106(1):262-4. No abstract available.

PMID:
8276194
33.

Oral and contact dissolution of gallstones.

Schoenfield LJ, Marks JW.

Am J Surg. 1993 Apr;165(4):427-30. Review.

PMID:
8480875
34.

A gelonin-containing immunotoxin directed against human breast carcinoma.

Rosenblum MG, Zuckerman JE, Marks JW, Rotbein J, Allen WR.

Mol Biother. 1992 Sep;4(3):122-9.

PMID:
1445665
35.

The sequence of biliary events preceding the formation of gallstones in humans.

Marks JW, Bonorris GG, Albers G, Schoenfield LJ.

Gastroenterology. 1992 Aug;103(2):566-70.

PMID:
1634075
36.

Risk factors for gallstone formation during rapid loss of weight.

Yang H, Petersen GM, Roth MP, Schoenfield LJ, Marks JW.

Dig Dis Sci. 1992 Jun;37(6):912-8.

PMID:
1587196
37.

Ulcer recurrence following duodenal ulcer healing with omeprazole, ranitidine, or placebo: a double-blind, multicenter, 6-month study. The Omeprazole Duodenal Ulcer Study Group.

Graham DY, Colon-Pagan J, Morse RS, Johnson TL, Walsh JH, McCullough AJ, Marks JW, Sklar M, Stone RC, Cagliola AJ, et al.

Gastroenterology. 1992 Apr;102(4 Pt 1):1289-94.

PMID:
1551535
38.

Factors affecting the measurement of cholesterol nucleation in human gallbladder and duodenal bile.

Marks JW, Broomfield P, Bonorris GG, Schoenfield LJ.

Gastroenterology. 1991 Jul;101(1):214-9.

PMID:
2044910
39.
40.

Gallstones: an update.

Schoenfield LJ, Carey MC, Marks JW, Thistle JL.

Am J Gastroenterol. 1989 Sep;84(9):999-1007. Review.

PMID:
2672795
41.

Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight.

Broomfield PH, Chopra R, Sheinbaum RC, Bonorris GG, Silverman A, Schoenfield LJ, Marks JW.

N Engl J Med. 1988 Dec 15;319(24):1567-72.

PMID:
3200265
42.

Dissolution of cholesterol gallstones by perfusion: a solution for the matrix?

Marks JW.

Hepatology. 1988 May-Jun;8(3):691-3. No abstract available.

PMID:
3371885
43.

Failure of episodic high-dose oral verapamil therapy to convert supraventricular tachycardia: a study of plasma verapamil levels and gastric motility.

Hamer AW, Tanasescu DE, Marks JW, Peter T, Waxman AD, Mandel WJ.

Am Heart J. 1987 Aug;114(2):334-42.

PMID:
3604891
44.

Effect of diet on dissolution of gallstones by ursodeoxycholic acid, including a comparison between ultrasonography and cholecystography.

Lefkof IR, Frenkiel PG, Lee DW, Cohen H, Bonorris GG, Gilmore CJ, Hamlin JA, Komaiko M, Resser K, Marks JW, et al.

Mt Sinai J Med. 1986 Apr;53(4):241-9. No abstract available.

PMID:
3014318
45.

The effect of diet on bile acid kinetics and biliary lipid secretion in gallstone patients treated with ursodeoxycholic acid.

Frenkiel PG, Lee DW, Cohen H, Gilmore CJ, Resser K, Bonorris GG, Marks JW, Schoenfield LJ.

Am J Clin Nutr. 1986 Feb;43(2):239-50.

PMID:
3004189
46.

Effect of dietary cholesterol on biliary lipids in patients with gallstones and normal subjects.

Lee DW, Gilmore CJ, Bonorris G, Cohen H, Marks JW, Cho-Sue M, Meiselman MS, Schoenfield LJ.

Am J Clin Nutr. 1985 Sep;42(3):414-20.

PMID:
4036847
47.
48.

Intermittency of cholesterol crystals in duodenal bile from gallstone patients.

Marks JW, Bonorris G.

Gastroenterology. 1984 Sep;87(3):622-7.

PMID:
6745615
49.

Cyclic nucleotides and glycoproteins during formation of cholesterol gallstones in prairie dogs.

Zak RA, Frenkiel PG, Marks JW, Bonorris GG, Allen A, Schoenfield LJ.

Gastroenterology. 1984 Aug;87(2):263-9.

PMID:
6329889
50.

Major issues in the organization and implementation of the National Cooperative Gallstone Study (NCGS).

Marks JW, Croke G, Gochman N, Hofmann AF, Lachin JM, Schoenfield LJ, Tyor MP, Hersh T, Hightower NC, Lasser EC, et al.

Control Clin Trials. 1984 Mar;5(1):1-12.

PMID:
6713905

Supplemental Content

Loading ...
Support Center